Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled crossover study of ivacaftor in cystic fibrosis with 3849+10kb C>T or D1152H mutations
MOH_2017-05-14_000384Phase 4Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ivacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Planned start Feb 2017; status: not yet recruiting.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2017-05-14_000384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-14_000384.